AEON Biopharma, Inc.
New York Stock Exchange AmericanCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Robert Bancroft
- Full Time Employees
- 5
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 4040 Macarthur Boulevard Newport Beach CA United States of America 92614
- IPO Date
- Jul 24, 2023
- CIK
- 0001837607
- Website
- aeonbiopharma.com
- Similar Companies
- Business
- AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the development of therapeutic botulinum toxin products, primarily its lead candidate ABP-450 (prabotulinumtoxinA), intended to treat an array of nervous system-related disorders. The company specializes in the formulation, development, and potential commercialization of botulinum toxin complex products for therapeutic indications including chronic and episodic migraine, cervical dystonia, gastroparesis, and post-traumatic stress disorder (PTSD). AEON Biopharma operates primarily in the United States, targeting the neurosciences market with its proprietary botulinum toxin injection designed to provide improved safety, tolerability, and efficacy compared to existing therapies. Founded in 2015 and headquartered in Irvine, California, AEON Biopharma aims to leverage its patented injection techniques and robust clinical trial program to deliver differentiated therapeutic options to patients, providers, and payors. In the last two years, AEON Biopharma has made significant strategic and financial advances. The company entered into a definitive business combination agreement in late 2022 to acquire Priveterra Acquisition Corp. in a reverse merger transaction expected to facilitate its Nasdaq listing under the ticker AEON and provide substantial capital for operations. In 2025, AEON successfully closed a private investment in public equity (PIPE) financing round totaling approximately $6 million initially, with prospects for up to $22 million through complementary transactions including a proposed convertible note exchange with Daewoong Pharmaceutical Co., Ltd., its strategic partner. These financings collectively reduced outstanding debt by over 90%, boosted the company’s balance sheet, accelerated the development timeline for ABP-450 by up to six months, and extended the company’s cash runway into the second quarter of 2026. AEON has progressed its regulatory strategy by preparing for a Biosimilar Biological Product Development (BPD) Type 2a meeting with the FDA in the second half of 2025, targeting the U.S. market entry of ABP-450 as a biosimilar to BOTOX (onabotulinumtoxinA). Analytical studies have demonstrated a 100% amino acid sequence match and high overall sequence coverage to BOTOX across five proteins, supporting its biosimilar designation pathway. The company’s current operations include ongoing enrollment and dosing in Phase II clinical trials assessing efficacy for migraine and cervical dystonia, with plans to expand indications based on a rigorous internal product assessment process aimed at maximizing clinical, regulatory, and commercial success. AEON's main products focus exclusively on therapeutic applications of botulinum toxin complexes, leveraging their proprietary prabotulinumtoxinA injection and patented delivery methods to treat muscle and nerve disorders. The company is dedicated to innovation within the therapeutic neurotoxin market, offering differentiated treatment paradigms with potential commercial scalability in the approximately $3.3 billion global therapeutic botulinum toxin segment. Its strategic partnerships, notably with Daewoong Pharmaceutical, provide operational and financial support to accelerate development and market positioning efforts. Overall, AEON Biopharma, Inc. stands as a developing biopharmaceutical entity focused on the neurosciences sector with advanced clinical-stage programs in botulinum toxin therapies, supported by recent transformative financial restructuring, regulatory milestones, and strategic collaborations headquartered in Irvine, California, and founded in 2015. Its core product, ABP-450, represents the company’s flagship candidate designed for U.S. biosimilar approval and commercial launch in therapeutic indications primarily for nerve and muscle disorders.
AEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
AEON Biopharma Sets Annual Shareholder Meeting
AEON Biopharma Sets Annual Shareholder Meeting
Aerovate Therapeutics (NASDAQ:AVTE) & AEON Biopharma (NASDAQ:AEON) Head to Head Survey
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711
AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards
AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program
AEON Biopharma (AEON) Projected to Post Quarterly Earnings on Wednesday
Financial Analysis: MindWalk (NASDAQ:HYFT) versus AEON Biopharma (NASDAQ:AEON)
AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions
Financial Comparison: Merck KGaA (OTCMKTS:MKGAF) versus AEON Biopharma (NASDAQ:AEON)
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711
AEON Biopharma Announces Execution of Exchange Agreement with Daewoong
AEON Biopharma Announces First Closing of PIPE Investment and Provides Update on FDA Type 2a Meeting Scheduling
AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth
AEON Biopharma Announces Fundraise Totaling Up to ~$22 Million through Private Placement and Proposed Exchange of Daewoong Convertible Notes
AEON Biopharma, Inc. (NASDAQ:AEON) Sees Significant Growth in Short Interest
AEON Biopharma Announces FDA BPD Type 2a Meeting for ABP-450 on November 19
AEON Biopharma Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Hexagon launches AEON, a humanoid built for industry